Bristol-Myers Squibb Announced Opdivo In Combination With Cabometyx Demonstrates Long-term Survival Benefits After Four Years Of Follow-up In The Checkmate -9er Trial In First-line Advanced Renal Cell Carcinoma
Portfolio Pulse from Charles Gross
Bristol Myers Squibb (BMY) and Exelixis, Inc. (EXEL) announced positive four-year follow-up results from the CheckMate -9ER trial for Opdivo and CABOMETYX in treating advanced renal cell carcinoma. The combination showed superior progression-free survival, objective response rates, and overall survival compared to sunitinib. The results, which also include health-related quality-of-life benefits, will be presented at the ASCO 2024 Genitourinary Cancers Symposium.
January 22, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's positive trial results for Opdivo in combination with CABOMETYX could boost investor confidence and potentially increase stock value due to the demonstrated long-term efficacy in treating advanced RCC.
The positive long-term results from the CheckMate -9ER trial are significant for Bristol Myers Squibb as they reinforce the efficacy of Opdivo in combination with CABOMETYX. This could lead to increased demand for the treatment, potentially boosting sales and positively impacting the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Exelixis, Inc.'s collaboration with BMY on the CheckMate -9ER trial and the positive results for CABOMETYX could positively influence its stock price as it may lead to increased sales and market confidence.
Exelixis, Inc. stands to benefit from the successful trial results of CABOMETYX in combination with Opdivo, as it may result in increased usage and sales. The positive data is likely to be well-received by investors and could lead to a short-term uptick in EXEL's stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90